Skip to main content

Zimmer Biomet Holdings (ZBH) Receives a Hold from Canaccord Genuity

Tipranks - Tipranks - Thu Feb 12, 6:42AM CST

In a report released today, Caitlin Cronin from Canaccord Genuity reiterated a Hold rating on Zimmer Biomet Holdings, with a price target of $93.00.

Valentine's Day Sale - 70% Off

According to TipRanks, Cronin is a 4-star analyst with an average return of 9.3% and a 50.43% success rate. Cronin covers the Healthcare sector, focusing on stocks such as Zimmer Biomet Holdings, TELA Bio, and Enovis.

In addition to Canaccord Genuity, Zimmer Biomet Holdings also received a Hold from Citi’s Joanne Wuensch in a report issued today. However, on the same day, TipRanks – PerPlexity upgraded Zimmer Biomet Holdings (NYSE: ZBH) to a Buy.

See Insiders’ Hot Stocks on TipRanks >>

Based on Zimmer Biomet Holdings’ latest earnings release for the quarter ending September 30, the company reported a quarterly revenue of $2 billion and a net profit of $230.9 million. In comparison, last year the company earned a revenue of $1.82 billion and had a net profit of $249.1 million

Read More on ZBH:

Disclaimer & DisclosureReport an Issue

This article contains syndicated content. We have not reviewed, approved, or endorsed the content, and may receive compensation for placement of the content on this site. For more information please view the Barchart Disclosure Policy here.
This section contains press releases and other materials from third parties (including paid content). The Globe and Mail has not reviewed this content. Please see disclaimer.

All market data (will open in new tab) is provided by Barchart Solutions. Copyright © 2026.

Information is provided 'as is' and solely for informational purposes, not for trading purposes or advice. For exchange delays and terms of use, please read disclaimer (will open in new tab).